Metagenomic Next-Generation Sequencing Revolutionizes Diagnosis of Central Nervous System Infections

Strategic Insights -

Pioneered by Delve Bio, a metagenomic next-generation sequencing (mNGS) platform has emerged as a crucial tool in diagnosing meningitis and encephalitis (M/E) by reducing the need for multiple tests and procedures. A recent study presented at IDWeek 2025 has demonstrated the potential of mNGS to streamline clinical workups and lower the cost of diagnosing M/E.

Key Takeaways:

  • A study conducted by researchers from Columbia University Irving Medical Center analyzed more than 80 patients and found that early use of mNGS testing could have saved over 280 microbiological tests.
  • The study also found that among patients with viral infections, early use of mNGS could have reduced over 90 microbiological tests and over 150 days to diagnosis.
  • In a cohort of seven patients with fungal infections, diagnosis would have been made earlier by over 61 days.
  • Delve Bio's metagenomic testing service, Delve Detect, provides comprehensive pathogen detection with a 48-hour turnaround time after sample receipt.
  • Delve Bio's Clinical Microbial Sequencing Board offers an on-call team of infectious disease experts who review results in clinical context.
  • The IDWeek 2025 meeting featured additional scientific presentations and education sessions on the use of mNGS in central nervous system infections.
  • A team from Children's Hospital of Colorado presented poster P-2004, highlighting the clinical utility of mNGS in conjunction with conventional microbiological testing for the diagnosis of suspected central nervous system (CNS) infections in children.
  • Delve Bio researchers presented poster P-1784, demonstrating a 86.1%/97.5% PPV/NPV that showcases Delve Detect as a sensitive and specific test of RNA and DNA pathogens from a single CSF sample.

Statistics:

  • mNGS testing could have saved over 280 microbiological tests.
  • Early use of mNGS could have reduced over 90 microbiological tests and over 150 days to diagnosis among patients with viral infections.
  • Diagnosis would have been made earlier by over 61 days in a cohort of seven patients with fungal infections.
  • Delve Detect provides comprehensive pathogen detection with a 48-hour turnaround time after sample receipt.
  • Over 20 percent increase in diagnostic yield observed with the Delve Detect platform.
  • The IDWeek 2025 meeting featured 4,000+ attendees.

Sources:

  • Delve Bio news release
  • IDWeek 2025 website
  • Journal of Clinical Microbiology
  • American Society for Microbiology